{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T12:57:20Z","timestamp":1792587440602,"version":"4.5.0"},"reference-count":77,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajkd.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1053\/j.ajkd.2020.12.020","type":"journal-article","created":{"date-parts":[[2021,3,8]],"date-time":"2021-03-08T19:58:35Z","timestamp":1615233515000},"page":"282-292","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":80,"title":["Assessing Risk of Rapid Progression in Autosomal Dominant Polycystic Kidney Disease and Special Considerations for Disease-Modifying Therapy"],"prefix":"10.1053","volume":"78","author":[{"given":"Fouad T.","family":"Chebib","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicente E.","family":"Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9569","key":"10.1053\/j.ajkd.2020.12.020_bib1","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/S0140-6736(07)60601-1","article-title":"Autosomal dominant polycystic kidney disease","volume":"369","author":"Torres","year":"2007","journal-title":"Lancet"},{"issue":"5","key":"10.1053\/j.ajkd.2020.12.020_bib2","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1053\/j.ajkd.2015.07.037","article-title":"Autosomal dominant polycystic kidney disease: core curriculum 2016","volume":"67","author":"Chebib","year":"2016","journal-title":"Am J Kidney Dis"},{"issue":"1 suppl 1","key":"10.1053\/j.ajkd.2020.12.020_bib3","doi-asserted-by":"crossref","first-page":"A6","DOI":"10.1053\/j.ajkd.2019.09.003","article-title":"US Renal Data System 2019 Annual Data Report: epidemiology of kidney disease in the United States","volume":"75","author":"Saran","year":"2020","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"10.1053\/j.ajkd.2020.12.020_bib4","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2215\/CJN.05900519","article-title":"Epidemiology of autosomal dominant polycystic kidney disease in Olmsted County","volume":"15","author":"Suwabe","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"10.1053\/j.ajkd.2020.12.020_bib5","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1159\/000494923","article-title":"Analysis of nationwide data to determine the incidence and diagnosed prevalence of autosomal dominant polycystic kidney disease in the USA: 2013-2015","volume":"5","author":"Willey","year":"2019","journal-title":"Kidney Dis"},{"issue":"10174","key":"10.1053\/j.ajkd.2020.12.020_bib6","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S0140-6736(18)32782-X","article-title":"Autosomal dominant\u00a0polycystic kidney disease","volume":"393","author":"Cornec-Le Gall","year":"2019","journal-title":"Lancet"},{"issue":"5","key":"10.1053\/j.ajkd.2020.12.020_bib7","doi-asserted-by":"crossref","first-page":"803","DOI":"10.2215\/CJN.06300615","article-title":"Effect of tolvaptan in autosomal dominant polycystic kidney disease by CKD stage: results from the TEMPO 3:4 trial","volume":"11","author":"Torres","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"issue":"13","key":"10.1053\/j.ajkd.2020.12.020_bib8","first-page":"1259","article-title":"Tolvaptan in autosomal dominant polycystic kidney disease","volume":"368","author":"Torres","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"20","key":"10.1053\/j.ajkd.2020.12.020_bib9","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1056\/NEJMoa1710030","article-title":"Tolvaptan in later-stage autosomal dominant polycystic kidney disease","volume":"377","author":"Torres","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1053\/j.ajkd.2020.12.020_bib10","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1681\/ASN.2017050483","article-title":"Genetic complexity of autosomal dominant polycystic kidney and liver diseases","volume":"29","author":"Cornec-Le Gall","year":"2018","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"7","key":"10.1053\/j.ajkd.2020.12.020_bib11","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.ekir.2019.04.018","article-title":"Intrafamilial variability of ADPKD","volume":"4","author":"Lanktree","year":"2019","journal-title":"Kidney Int Rep"},{"issue":"11","key":"10.1053\/j.ajkd.2020.12.020_bib12","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1681\/ASN.2013111184","article-title":"Predictors of autosomal dominant polycystic kidney disease progression","volume":"25","author":"Schrier","year":"2014","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"6","key":"10.1053\/j.ajkd.2020.12.020_bib13","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1038\/ki.2014.120","article-title":"Analysis of data from the ERA-EDTA Registry indicates that conventional treatments for chronic kidney disease do not reduce the need for renal replacement therapy in autosomal dominant polycystic kidney disease","volume":"86","author":"Spithoven","year":"2014","journal-title":"Kidney Int"},{"issue":"3","key":"10.1053\/j.ajkd.2020.12.020_bib14","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1681\/ASN.2015010016","article-title":"The PROPKD score: a new algorithm to predict renal survival in autosomal dominant polycystic kidney disease","volume":"27","author":"Cornec-Le Gall","year":"2016","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"20","key":"10.1053\/j.ajkd.2020.12.020_bib15","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1056\/NEJMoa054341","article-title":"Volume progression in polycystic kidney disease","volume":"354","author":"Grantham","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1053\/j.ajkd.2020.12.020_bib16","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.ekir.2017.01.003","article-title":"Total kidney volume is a prognostic biomarker of renal function decline and progression to end-stage renal disease in patients with autosomal dominant polycystic kidney disease","volume":"2","author":"Perrone","year":"2017","journal-title":"Kidney Int Rep"},{"issue":"5","key":"10.1053\/j.ajkd.2020.12.020_bib17","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/j.kint.2018.12.023","article-title":"Long-term trajectory of kidney function in autosomal-dominant polycystic kidney disease","volume":"95","author":"Yu","year":"2019","journal-title":"Kidney Int"},{"issue":"1","key":"10.1053\/j.ajkd.2020.12.020_bib18","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1681\/ASN.2013101138","article-title":"Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials","volume":"26","author":"Irazabal","year":"2015","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"3","key":"10.1053\/j.ajkd.2020.12.020_bib19","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.kint.2017.09.027","article-title":"Baseline total kidney\u00a0volume and the rate of kidney growth are associated with chronic kidney disease progression in autosomal dominant\u00a0polycystic kidney disease","volume":"93","author":"Yu","year":"2018","journal-title":"Kidney Int"},{"issue":"1","key":"10.1053\/j.ajkd.2020.12.020_bib20","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1186\/s12882-017-0654-y","article-title":"Temporal and geographical external validation study and extension of the Mayo Clinic prediction model to predict eGFR in the younger population of Swiss ADPKD patients","volume":"18","author":"Girardat-Rotar","year":"2017","journal-title":"BMC Nephrol"},{"key":"10.1053\/j.ajkd.2020.12.020_bib21","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/9286728","article-title":"Renal volume in ADPKD patient evaluation","volume":"2020","author":"Galliani","year":"2020","journal-title":"Int J Nephrol"},{"issue":"7","key":"10.1053\/j.ajkd.2020.12.020_bib22","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1681\/ASN.2019101121","article-title":"Expanded imaging classification of autosomal dominant polycystic kidney disease","volume":"31","author":"Bae","year":"2020","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"4","key":"10.1053\/j.ajkd.2020.12.020_bib23","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s10157-015-1219-7","article-title":"Evidence-based clinical practice guidelines for polycystic kidney disease 2014","volume":"20","author":"Horie","year":"2016","journal-title":"Clin Exp Nephrol"},{"issue":"11","key":"10.1053\/j.ajkd.2020.12.020_bib24","doi-asserted-by":"crossref","first-page":"3013","DOI":"10.1681\/ASN.2006080835","article-title":"Cyst number but not the rate of cystic growth is associated with the mutated gene in autosomal dominant polycystic kidney disease","volume":"17","author":"Harris","year":"2006","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"1","key":"10.1053\/j.ajkd.2020.12.020_bib25","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/ki.2015.71","article-title":"A\u00a0comparison of ultrasound and magnetic resonance imaging shows that kidney length predicts chronic kidney disease in autosomal dominant polycystic kidney disease","volume":"88","author":"Bhutani","year":"2015","journal-title":"Kidney Int"},{"issue":"3","key":"10.1053\/j.ajkd.2020.12.020_bib26","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1007\/s00261-020-02748-4","article-title":"Automatic semantic segmentation of kidney cysts in MR images of patients affected by autosomal-dominant polycystic kidney disease","volume":"46","author":"Kline","year":"2021","journal-title":"Abdom Radiol (NY)"},{"issue":"2","key":"10.1053\/j.ajkd.2020.12.020_bib27","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1159\/000442296","article-title":"3 Tesla-diffusion tensor imaging in autosomal dominant polycystic kidney disease: the nephrologist\u2019s point of view","volume":"134","author":"Lupica","year":"2016","journal-title":"Nephron"},{"issue":"5","key":"10.1053\/j.ajkd.2020.12.020_bib28","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/RLI.0b013e3181d83abc","article-title":"Diffusion tensor\u00a0imaging (DTI) of the kidney at 3 Tesla-feasibility, protocol evaluation and comparison to 1.5 Tesla","volume":"45","author":"Notohamiprodjo","year":"2010","journal-title":"Invest Radiol"},{"issue":"5","key":"10.1053\/j.ajkd.2020.12.020_bib29","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1016\/j.kint.2017.03.026","article-title":"Image texture features predict renal function decline in patients with autosomal dominant polycystic kidney disease","volume":"92","author":"Kline","year":"2017","journal-title":"Kidney Int"},{"issue":"4","key":"10.1053\/j.ajkd.2020.12.020_bib30","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1002\/mrm.25701","article-title":"Utilizing magnetization transfer imaging to investigate tissue remodeling in a murine model of autosomal dominant polycystic kidney disease","volume":"75","author":"Kline","year":"2016","journal-title":"Magn Reson Med"},{"issue":"4","key":"10.1053\/j.ajkd.2020.12.020_bib31","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/RLI.0000000000000633","article-title":"Magnetic resonance kidney parenchyma-t2 as a novel imaging biomarker for autosomal dominant polycystic kidney disease","volume":"55","author":"Siedek","year":"2020","journal-title":"Invest Radiol"},{"issue":"19","key":"10.1053\/j.ajkd.2020.12.020_bib32","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1001\/jama.2018.15870","article-title":"Effect of lanreotide on kidney function in patients with autosomal dominant polycystic kidney disease: the DIPAK 1 randomized clinical trial","volume":"320","author":"Meijer","year":"2018","journal-title":"JAMA"},{"issue":"15","key":"10.1053\/j.ajkd.2020.12.020_bib33","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.138724","article-title":"The value of genotypic and imaging information to predict functional and structural outcomes in ADPKD","volume":"5","author":"Lavu","year":"2020","journal-title":"JCI Insight"},{"issue":"6","key":"10.1053\/j.ajkd.2020.12.020_bib34","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1681\/ASN.2015060648","article-title":"Refining genotype-phenotype correlation in autosomal dominant polycystic kidney disease","volume":"27","author":"Hwang","year":"2016","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"6","key":"10.1053\/j.ajkd.2020.12.020_bib35","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1681\/ASN.2012070650","article-title":"Type of PKD1 mutation influences renal outcome in ADPKD","volume":"24","author":"Cornec-Le Gall","year":"2013","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"4","key":"10.1053\/j.ajkd.2020.12.020_bib36","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1053\/j.ajkd.2017.01.046","article-title":"PKD2-related autosomal dominant polycystic kidney disease: prevalence, clinical presentation, mutation spectrum, and prognosis","volume":"70","author":"Cornec-Le Gall","year":"2017","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"10.1053\/j.ajkd.2020.12.020_bib37","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1097\/01.ASN.0000061774.90975.25","article-title":"Genotype-renal function correlation in type 2 autosomal dominant polycystic kidney disease","volume":"14","author":"Magistroni","year":"2003","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"9147","key":"10.1053\/j.ajkd.2020.12.020_bib38","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0140-6736(98)03495-3","article-title":"Comparison of phenotypes\u00a0of polycystic kidney disease types 1 and 2. European\u00a0PKD1-PKD2 Study Group","volume":"353","author":"Hateboer","year":"1999","journal-title":"Lancet"},{"issue":"8","key":"10.1053\/j.ajkd.2020.12.020_bib39","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1681\/ASN.2009020162","article-title":"Family history of renal disease severity predicts the mutated gene in ADPKD","volume":"20","author":"Barua","year":"2009","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"1","key":"10.1053\/j.ajkd.2020.12.020_bib40","first-page":"1","article-title":"KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"3","year":"2013","journal-title":"Kidney Int Suppl"},{"issue":"3","key":"10.1053\/j.ajkd.2020.12.020_bib41","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1093\/ndt\/gfv456","article-title":"Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice","volume":"31","author":"Gansevoort","year":"2016","journal-title":"Nephrol Dial Transplant"},{"issue":"12","key":"10.1053\/j.ajkd.2020.12.020_bib42","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/nrneph.2017.127","article-title":"New treatment paradigms for ADPKD: moving towards precision medicine","volume":"13","author":"Lanktree","year":"2017","journal-title":"Nat Rev Nephrol"},{"issue":"2","key":"10.1053\/j.ajkd.2020.12.020_bib43","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1681\/ASN.2017070819","article-title":"Overweight and obesity are predictors of progression in early autosomal dominant polycystic kidney disease","volume":"29","author":"Nowak","year":"2018","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"1","key":"10.1053\/j.ajkd.2020.12.020_bib44","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.kint.2019.02.037","article-title":"What can copeptin tell us in patients with autosomal dominant polycystic disease?","volume":"96","author":"Bankir","year":"2019","journal-title":"Kidney Int"},{"issue":"1","key":"10.1053\/j.ajkd.2020.12.020_bib45","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.kint.2018.11.044","article-title":"Plasma copeptin levels predict disease progression and tolvaptan efficacy in autosomal dominant polycystic kidney disease","volume":"96","author":"Gansevoort","year":"2019","journal-title":"Kidney Int"},{"issue":"6","key":"10.1053\/j.ajkd.2020.12.020_bib46","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1007\/s10157-015-1101-7","article-title":"Association of arginine vasopressin surrogate marker urinary copeptin with severity of autosomal dominant polycystic kidney disease (ADPKD)","volume":"19","author":"Nakajima","year":"2015","journal-title":"Clin Exp Nephrol"},{"issue":"11","key":"10.1053\/j.ajkd.2020.12.020_bib47","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1093\/ndt\/gfv422","article-title":"Albuminuria and tolvaptan in autosomal-dominant polycystic kidney disease: results of the TEMPO 3:4 Trial","volume":"31","author":"Gansevoort","year":"2016","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"10.1053\/j.ajkd.2020.12.020_bib48","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1681\/ASN.2016040448","article-title":"Urine osmolality, response to tolvaptan, and outcome in autosomal dominant polycystic kidney disease: results from the TEMPO 3:4 trial","volume":"28","author":"Devuyst","year":"2017","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"5","key":"10.1053\/j.ajkd.2020.12.020_bib49","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0233213","article-title":"Urinary metabolites associate with the rate of kidney function decline in patients with autosomal dominant polycystic kidney disease","volume":"15","author":"Dekker","year":"2020","journal-title":"PLoS One"},{"issue":"5","key":"10.1053\/j.ajkd.2020.12.020_bib50","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1159\/000502999","article-title":"Rapid progression of autosomal dominant polycystic kidney disease: urinary biomarkers as predictors","volume":"50","author":"Messchendorp","year":"2019","journal-title":"Am J Nephrol"},{"issue":"2","key":"10.1053\/j.ajkd.2020.12.020_bib51","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.ekir.2017.10.004","article-title":"Urinary biomarkers to identify autosomal dominant polycystic kidney disease patients with a high likelihood of disease progression","volume":"3","author":"Messchendorp","year":"2018","journal-title":"Kidney Int Rep"},{"issue":"1","key":"10.1053\/j.ajkd.2020.12.020_bib52","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0053016","article-title":"Urinary proteomic biomarkers for diagnosis and risk stratification of autosomal dominant polycystic kidney disease: a multicentric study","volume":"8","author":"Kistler","year":"2013","journal-title":"PLoS One"},{"key":"10.1053\/j.ajkd.2020.12.020_bib53","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2147\/IJNRD.S125942","article-title":"Tolvaptan in the treatment of autosomal dominant polycystic kidney disease: patient selection and special considerations","volume":"11","author":"Sans-Atxer","year":"2018","journal-title":"Int J Nephrol Renovasc Dis"},{"issue":"10","key":"10.1053\/j.ajkd.2020.12.020_bib54","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1681\/ASN.2018060590","article-title":"A\u00a0practical guide for treatment of rapidly progressive ADPKD with tolvaptan","volume":"29","author":"Chebib","year":"2018","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2020.12.020_bib55","doi-asserted-by":"crossref","DOI":"10.1177\/2054358118801589","article-title":"Updated Canadian expert consensus on assessing risk of disease progression and pharmacological management of autosomal dominant polycystic kidney disease","volume":"5","author":"Soroka","year":"2018","journal-title":"Can J Kidney Health Dis"},{"key":"10.1053\/j.ajkd.2020.12.020_bib56","author":"Ong"},{"key":"10.1053\/j.ajkd.2020.12.020_bib59","series-title":"ADPKD: Risk Prediction for Treatment Selection","author":"Messchendorp","year":"2019"},{"issue":"4","key":"10.1053\/j.ajkd.2020.12.020_bib60","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1159\/000502634","article-title":"Comparison of different selection strategies for tolvaptan eligibility among autosomal dominant polycystic kidney disease patients","volume":"50","author":"Wulfmeyer","year":"2019","journal-title":"Am J Nephrol"},{"issue":"4","key":"10.1053\/j.ajkd.2020.12.020_bib61","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1159\/000493325","article-title":"Autosomal dominant polycystic kidney disease: clinical assessment of rapid progression","volume":"48","author":"Furlano","year":"2018","journal-title":"Am J Nephrol"},{"issue":"2","key":"10.1053\/j.ajkd.2020.12.020_bib62","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/ki.2008.558","article-title":"Increases in kidney volume in autosomal dominant polycystic kidney disease can be detected within 6 months","volume":"75","author":"Kistler","year":"2009","journal-title":"Kidney Int"},{"issue":"8","key":"10.1053\/j.ajkd.2020.12.020_bib63","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1681\/ASN.V1181505","article-title":"Quantification and longitudinal trends of kidney, renal cyst, and renal parenchyma volumes in autosomal dominant polycystic kidney disease","volume":"11","author":"King","year":"2000","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"4","key":"10.1053\/j.ajkd.2020.12.020_bib64","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1097\/00004728-200007000-00019","article-title":"Volumetric measurement of renal cysts and parenchyma using MRI: phantoms and patients with polycystic kidney disease","volume":"24","author":"Bae","year":"2000","journal-title":"J\u00a0Comput Assist Tomogr"},{"issue":"8","key":"10.1053\/j.ajkd.2020.12.020_bib65","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1681\/ASN.2018090902","article-title":"Automatic measurement of kidney and liver volumes from MR images of patients affected by autosomal dominant polycystic kidney disease","volume":"30","author":"van Gastel","year":"2019","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"2","key":"10.1053\/j.ajkd.2020.12.020_bib66","first-page":"241","article-title":"Automatic total kidney volume measurement on follow-up magnetic resonance images to facilitate monitoring of autosomal dominant polycystic kidney disease progression","volume":"31","author":"Kline","year":"2016","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"10.1053\/j.ajkd.2020.12.020_bib67","doi-asserted-by":"crossref","first-page":"10996","DOI":"10.1038\/s41598-019-47206-4","article-title":"Prognostic performance of kidney volume measurement for polycystic kidney disease: a comparative study of ellipsoid vs. manual segmentation","volume":"9","author":"Shi","year":"2019","journal-title":"Sci Rep"},{"key":"10.1053\/j.ajkd.2020.12.020_bib68","doi-asserted-by":"crossref","DOI":"10.34067\/KID.0003912020","article-title":"Assessing polycystic kidney disease in rodents: comparison of robotic 3D ultrasound and magnetic resonance imaging","author":"Beaumont","year":"2020","journal-title":"Kidney360"},{"issue":"11","key":"10.1053\/j.ajkd.2020.12.020_bib69","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.2215\/CJN.03960318","article-title":"Recent Advances in the management of autosomal dominant polycystic kidney disease","volume":"13","author":"Chebib","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"10.1053\/j.ajkd.2020.12.020_bib70","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1093\/ndt\/gfy297","article-title":"Pro: tolvaptan delays the progression of autosomal dominant polycystic kidney disease","volume":"34","author":"Torres","year":"2019","journal-title":"Nephrol Dial Transplant"},{"issue":"8","key":"10.1053\/j.ajkd.2020.12.020_bib71","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.2215\/CJN.01520218","article-title":"Long-term administration of tolvaptan in autosomal dominant polycystic kidney disease","volume":"13","author":"Edwards","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"issue":"25","key":"10.1053\/j.ajkd.2020.12.020_bib72","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","article-title":"Tolvaptan in patients with autosomal dominant polycystic kidney disease","volume":"367","author":"Torres","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"20","key":"10.1053\/j.ajkd.2020.12.020_bib73","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","article-title":"The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group","volume":"329","author":"Lewis","year":"1993","journal-title":"N\u00a0Engl J Med"},{"issue":"10022","key":"10.1053\/j.ajkd.2020.12.020_bib74","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S0140-6736(15)01225-8","article-title":"Blood pressure lowering\u00a0for\u00a0prevention of cardiovascular disease and death: a systematic review and meta-analysis","volume":"387","author":"Ettehad","year":"2016","journal-title":"Lancet"},{"issue":"3","key":"10.1053\/j.ajkd.2020.12.020_bib75","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/j.1600-6143.2010.03283.x","article-title":"Long-term renal allograft survival in the United States: a critical reappraisal","volume":"11","author":"Lamb","year":"2011","journal-title":"Am J Transplant"},{"issue":"2","key":"10.1053\/j.ajkd.2020.12.020_bib76","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1097\/MOT.0b013e328344bfd6","article-title":"The elderly as recipients of living donor kidneys, how old is too old?","volume":"16","author":"Cooper","year":"2011","journal-title":"Curr Opin Organ Transplant"},{"issue":"5","key":"10.1053\/j.ajkd.2020.12.020_bib77","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1007\/s00467-017-3584-9","article-title":"Tolvaptan treatment for severe neonatal autosomal-dominant polycystic kidney disease","volume":"32","author":"Gilbert","year":"2017","journal-title":"Pediatr Nephrol"},{"issue":"6","key":"10.1053\/j.ajkd.2020.12.020_bib78","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.ekir.2017.07.004","article-title":"Tolerability of aquaretic-related symptoms following tolvaptan for autosomal dominant polycystic kidney disease: results from TEMPO 3:4","volume":"2","author":"Devuyst","year":"2017","journal-title":"Kidney Int Rep"},{"issue":"1","key":"10.1053\/j.ajkd.2020.12.020_bib79","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s12882-018-0957-7","article-title":"Case report: a thiazide diuretic to treat polyuria induced by tolvaptan","volume":"19","author":"Kramers","year":"2018","journal-title":"BMC Nephrol"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S027263862100439X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S027263862100439X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T03:39:16Z","timestamp":1759462756000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S027263862100439X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":77,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["S027263862100439X"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2020.12.020","relation":{},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Assessing Risk of Rapid Progression in Autosomal Dominant Polycystic Kidney Disease and Special Considerations for Disease-Modifying Therapy","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2020.12.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 by the National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}]}}